Advances in Systemic Therapy for Unresectable Hepatocellular Carcinoma: Commentary on The Impact of the STRIDE Regimen in HIMALAYA Trial.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Unresectable hepatocellular carcinoma (HCC) remains a global challenge, with limited effective treatment options for advanced-stage disease. The HIMALAYA trial (phase III randomized study that evaluated the STRIDE regimen) introduced the Single Tremelimumab Regular Interval Durvalumab (STRIDE) regimen, an immunotherapy-based approach that achieved a median overall survival (OS) of 16.43 months compared to 13.77 months with sorafenib. While statistically significant, this ~2.7 months OS gain warrants scrutiny in light of STRIDE's increased immune-related toxicity and cost. This commentary evaluates STRIDE's impact within the broader landscape of first-line systemic therapy for unresectable HCC, alongside other regimens such as atezolizumab plus bevacizumab and nivolumab plus ipilimumab. We explore STRIDE's mechanism of action, safety profile, modest progression-free survival (PFS) improvement, and implementation challenges, incorporating insights from 2023-2025 research. In addition, we discussed its limitations in non-viral HCC and Child-Pugh B patients, the role of emerging biomarkers, and the potential of radiation to enhance immunotherapy efficacy. As a dual immune checkpoint inhibitor (ICI) strategy, STRIDE offers an important advance that may not only extend survival but also open the door to future curative approaches. However, optimizing its use will require refined patient selection and further investigation of synergistic combination therapies.